Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Daily News

No Stents in STEMI? With Careful Selection, Maybe

Caitlin E. Cox

March 21, 2022

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Industry News

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

September 16, 2016

News Industry News

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

July 11, 2016

News Industry News

Avinger Announces FDA Clearance and U.S. Launch of Breakthrough Treatment for Patients With Peripheral Artery Disease

March 01, 2016

News Conference News TCT 2015

VISION: OCT-Guided Atherectomy Safe, Effective for PAD Intervention

October 14, 2015

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

News Conference News ESC 2013

AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction

Caitlin E. Cox

September 04, 2013

Advertisement

No Stents in STEMI? With Careful Selection, Maybe

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

Avinger Announces FDA Clearance and U.S. Launch of Breakthrough Treatment for Patients With Peripheral Artery Disease

VISION: OCT-Guided Atherectomy Safe, Effective for PAD Intervention

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content